Medication

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and…

Flowers produce oils mainly to attract pollinators such as bees and butterflies. As a result, flower oils are…

The Healing the Collective Faire brought a wide range of holistic wellness resources to Great Falls over the…

Most years, when thousands of psychiatrists gather for the annual meeting of the American Psychiatric Association, they walk…

Researchers found that many commonly prescribed drugs, not just antibiotics, were linked to long-lasting microbial changes that could…

People on SSRIs should be ‘extra careful’ this summer (Credits: Bloomberg via Getty Images) While the UK basks…

Ashwagandha remains one of the most recognized Indian herbal ingredients globally, with the Indian Ashwagandha supplements market valued…

Experts claim that consistent sessions can help treat an array of respiratory issues like snoring, asthma, wheezing, chronic…

A wave of prescription weight-loss medications has swept across Australia, reshaping how doctors treat obesity and forcing regulators…

The Food and Drug Administration (FDA) approved Hepcludex on Friday for the treatment of chronic hepatitis D, ending…

NEW DELHI: Amid rising reports of young people misusing Pregabalin for its sedative, euphoric and dissociative effects, the…

Patna: Residents across the city faced inconvenience on Wednesday as medicine shops remained closed during a nationwide strike…

A single dose of Lilly’s PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia